NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

BioRestorative Therapies, Inc. (BRTX) Stock Analysis

BioRestorative Therapies, Inc. (BRTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BRTX

$0.15

+$0.00 (+2.99%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BRTX with… →

BRTX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.15
Previous Close
$0.14
Day's Range
0.14–0.15
52-Week Range
0.14–1.73
Volume
764.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.74
Valuation
Market Cap
$4.09M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.42
EPS (ttm)Profit attributable to each share over the last twelve months.
−21.83
Financials (FY)
Revenue (FY)
$359.70K−10.30%
Net Income (FY)
−$14.24M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
27.62M
1-Year Return
−90.92%
Dividend and dates
Avg Volume
458.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BRTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−87.40%
2025−17.83%
2024−17.81%
2023−36.73%
2022−36.64%
2021−84.28%
2020+38.00%
2019−99.44%
2018−75.68%
2017+12.12%
2016 (partial year)+6.80%

As of September 4, 2026.

BRTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$359.70K−$14.24M−3959.4%
2024$401.00K−$8.98M−2239.2%
2023$145.80K−$10.42M−7145.2%
2022$119.80K−$13.22M−11037.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$359.70K$335.86K−$15.65M−$14.24M−3959.4%
2024$401.00K$372.93K−$11.56M−$8.98M−2239.2%
2023$145.80K$145.80K−$15.14M−$10.42M−7145.2%
2022$119.80K—−$18.86M−$13.22M−11037.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BRTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricBRTXBiotechnology medianvs median
P/S ratio11.4215.2625% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values BioRestorative Therapies, Inc. (BRTX) at $4.09M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 13.

Over the past 52 weeks the price has ranged from $0.14 to $1.73. BRTX last closed at $0.15 on September 4, 2026. That is $0.00 (+2.99%) against the previous close. The latest close sits 3.86% above that 52-week low.

Financial Health

In fiscal 2025, BioRestorative Therapies, Inc. reported revenue of $359.70K. That is −10.30% against the prior fiscal year, when revenue was $401.00K. The same year closed with a net loss of $14.24M. The reported profit margin is 0%. Trailing earnings per share are −21.83.

Across the 4 fiscal years on file, revenue moves from $119.80K in 2022 to $359.70K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 11.42. On price-to-sales that is 25.16% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.74. Daily returns over the trailing 10 years annualize to a volatility of 270.59%. The trailing one-year price return is −90.92%. Measured over 10 years, that is −68.11% a year compounded.

Growth & Income

No dividend is on file for BRTX.

So far in 2026 the price is −87.40%. Across the complete calendar years on file, 2020 returned +38.00% and 2019 returned −99.44%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

BioRestorative Therapies, Inc. (BRTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioRestorative Therapies, Inc. BRTX $4.09M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. BioRestorative Therapies, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Visit website →